http://www.biospace.comBioSpace RSS GeneratorThu, 02 Jul 2009 18:29:10 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2009http://www.biospace.com/news_story.aspx?StoryID=148609&full=1Bloomberg -- Johnson & Johnson agreed to pay $1 billion for a stake in Elan Corp. and will develop the Irish drugmakers medicines against Alzheimers disease.Thu, 02 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148608&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 02 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148607&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 02 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148458&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148575&full=1BizJournals -- Maxygen Inc. and Japanese drug maker Astellas Pharma Inc. will start an R&D joint venture focused on protein drugs but largely spelling the beginning of the end of the Redwood City company as it is known today.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148439&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148456&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148452&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148497&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148460&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148448&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148453&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148525&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148438&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148451&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148464&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148443&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148457&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148446&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148442&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148455&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148504&full=1<p>Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study</p><p></p><p>AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., today announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148508&full=1<p>ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE). </p><p></p><p>(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148502&full=1<p>VYVANSE is the first stimulant to establish duration of efficacy from two hours up to 14 hours after administration in adults with ADHD</p><p></p><p>HOLLYWOOD, Fla., July 1 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE(R) (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148518&full=1KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis. PH-10 is the Company's topical drug for the treatment of dermatologic diseases, including atopic dermatitis, a chronic skin condition that includes some forms of...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148520&full=1THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics (NasdaqGM:RPRX) announced today that an end of Phase II meeting is scheduled with the Food and Drug Administration (FDA) for late September 2009 to discuss a Phase III program investigating the use of Proellex in the treatment of endometriosis.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148528&full=1<div id"releaseBody"><p>BUDAPEST, HUNGARY--(Marketwire - July 01, 2009) - Power of the Dream Ventures, Inc. (OTCBB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerPWRV">PWRV</a>), Hungary's premier technology acquisition and development company, ispleased to present this Genetic Immunity release, based on a previouslyannounced agreement whereby Power of the Dream Ventures will issue...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148530&full=1<div id"releaseBody"><p>HUNT VALLEY, MD--(Marketwire - July 01, 2009) - Cardioxyl Pharmaceuticals, Inc., a clinicalstage pharmaceutical company developing therapeutic agents for thetreatment of cardiovascular disease, today announced the initiation of aPhase I/IIa dose-escalation study of lead drug candidate, CXL-1020, for thetreatment of acute decompensated heart failure (ADHF). The...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148501&full=1LIVINGSTON, N.J.--(BUSINESS WIRE)--Some patients who suffer from recurrent cancer at the chest wall now have another option. The Radiation Oncology Department at Saint Barnabas Medical Center is one of a few hospitals nationwide to participate in a study which combines the use of the heat-sensitive chemotherapeutic agent ThermoDox with microwave hyperthermia, or heat.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148552&full=1CSL Limited, Australias leading biopharmaceutical company, will shortly be commencing a clinical trial of a candidate vaccine against Novel H1N1 Swine Flu. The trial will be undertaken in partnership with Clinical Research Organisation CMAX and the Royal Adelaide Hospital in South Australia.</p><p>Healthy adults aged between 18 and 64 years are being sought to participate, and must be available...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148555&full=1Leiden, The Netherlands, July 1, 2009. Biotech company Pharming Group NV (Pharming or the Company) (NYSE Euronext: PHARM) today announced that, as part of the activities for the regulatory submission files, it has now also completed the final analysis of its Rhucin randomised placebo-controlled studies. The results confirm the positive and consistent efficacy and safety of Rhucin in the treatment...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148592&full=1<p> REYKJAVIK, Iceland, July 1 /PRNewswire-FirstCall/ -- The largest study of the genetics of schizophrenia ever undertaken has revealed several new common single-letter variants in the sequence of the human genome (SNPs) linked to risk of the disease. The study, by a multinational consortium of scientists led by a team from deCODE genetics , analyzed the genomes of more than 50,000 patients and...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148490&full=1BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America Holdings (NYSE: LH) today announced the commencement of its cash tender offer for all outstanding shares of the common stock of Monogram Biosciences, Inc. (NASDAQ: MGRM) for $4.55 per share. The tender offer is being made by Mastiff Acquisition Corp., a wholly owned subsidiary of LabCorp, pursuant to an Offer to Purchase, dated July...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148498&full=1RALEIGH, N.C.--(BUSINESS WIRE)--INC Research, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, today announced it has completed the acquisition of the Phase II-IV operations (Global Clinical Development) of MDS Pharma Services, a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ).Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148580&full=1<div id"releaseBody"><p>PARIS--(Marketwire - July 01, 2009) - <table class"releaseLink"><tr><td class"releaseLink"><b>Highlighted Links</b></td></tr><tr><td><p>&nbsp;</p><a href"http://www2.marketwire.com/mw/mmframe?prid515587&attachid1014928">companynewsgroup Home Page</a></td></tr></table> A deal focusing on reinforcing its position in thenordic area (Sweden, Norway, Finland &amp; Denmark...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148560&full=1London, UK, 1 July 2009 - Ark Therapeutics Group plc (Ark or the Company) announces today that it has signed an agreement with the private Finnish biotechnology company, Oy Lx Therapies Ltd (Lx Therapies), to produce Vascular Endothelial Growth Factor C in an Adenoviral Vector (Ad VEGF-C). Under the agreement, Ark will undertake all manufacturing and filling activities for pre-clinical use and...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148563&full=1La Jolla, CA July 1, 2009 Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation from The Regents of the University of California. These proprietary osteogenic agents were developed by Farhad Parhami, Ph.D., professor of medicine at University of California, Los Angeles, in...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148531&full=1<div id"releaseBody"><p>BUFFALO, NY--(Marketwire - July 01, 2009) - Cleveland BioLabs, Inc. (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerCBLI">CBLI</a>) todayannounced that the Chemical Biological Medical Systems MedicalIdentification and Treatment Systems Joint Product Management Office(CBMS-MITS JPMO) of The Department of Defense (DoD) has exercised thecontract...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148589&full=1<p>LA JOLLA, Calif., July 1 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation from The Regents of the University of California. These proprietary osteogenic agents were developed by Farhad Parhami, Ph.D., professor of medicine at University of California, Los...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148526&full=1PHILADELPHIA & HONG KONG--(BUSINESS WIRE)--MacKay Life Sciences, Inc. (MLS) (formerly Biofield Corp. (OTCBB:BZEC), today announced that it has signed a binding Memorandum Of Agreement (MOU) with the master licensee to complete the long awaited reacquisition of the master license agreement (the MLA) that the company had previously granted to the MacKay Group Limited (MKG). MKG has since transferred...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148506&full=1CARLSBAD, Calif. & BEIJING--(BUSINESS WIRE)--Applied Biosystems, part of Life Technologies Corporation (NASDAQ: LIFE), today announced that it is assisting the Chinese government in reinforcing new standards for food safety in China. As part of its effort to enhance its ability to monitor the domestic food supply in addition to global exports, the Chinese General Administration of Quality Supervision...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148583&full=1NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced that it has updated the U.S. product labeling for CHANTIX (varenicline), a prescription aid to smoking cessation treatment, to communicate important safety information in a boxed warning as well as in revised warnings and precautions. These updates are based on post-marketing reports and are being made in agreement with the U.S. Food and Drug Administration...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148584&full=1NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites media and investors to listen to a teleconference related to CHANTIX at 1:15 PM US/EST on Wednesday, July 1. In addition to providing an update on CHANTIX, Pfizer scientists will answer press questions on the information provided.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148512&full=1<p>TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. today announced that it has been awarded a European patent for a novel device and methods for linking biological agents to labels for diagnostic and therapeutic applications. The technology, which is known as In-Line labeling, was developed for the production of radiolabeled anti-cancer antibodies, but is applicable...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148550&full=1MILWAUKEE, Wis. (July 1, 2009) Prodesse Inc., a molecular diagnostics company focused on infectious disease, today announced that it has taken worldwide, non-exclusive sublicenses with Abbott for the Caskey (U.S. No. 5,582,989) and Stanbridge (U.S. No. 5,851,767) patents. These patents were exclusively licensed to Abbott, with the right to grant sublicenses, by the Baylor College of Medicine and...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148469&full=1pehub.com -- ProCertus BioPharm Inc., a Madison, Wisc.-based developer of drugs to treat the side effects of chemotherapy and radiotherapy on cancer patients, has raised $2.1 million in new VC funding. Return backers include Novartis Venture Fund and Venture Investors LLC.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148449&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148522&full=1BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc (TSX Venture: IXS) today announced that its shareholders have approved all resolutions at the Annual Shareholders Meeting.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148523&full=1NEW YORK--(BUSINESS WIRE)--Medidata Solutions (Nasdaq: MDSO), a leading global provider of hosted clinical development solutions, today announced that the underwriters of its initial public offering exercised in full their over-allotment option to purchase an additional 945,000 shares of Medidatas common stock at a public offering price of $14.00 per share, less underwriting discounts and commissions...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148532&full=1<div id"releaseBody"><p>COSTA MESA, CA--(Marketwire - July 01, 2009) - CNS Response, Inc. (OTCBB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerCNSO">CNSO</a>) (the"Company") is issuing this press release in order to provide itsstockholders with information regarding one or more communications thatthey may have received in the mail captioned "Notice of Special Meeting ofStockholders...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148533&full=1<div id"releaseBody"><p>XI'AN, CHINA--(Marketwire - June 30, 2009) - Skystar Bio-Pharmaceutical Co., Ltd. (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerSKBI">SKBI</a>), a China-based producer and distributor of veterinary medicines,vaccines, micro-organisms and feed additives, today announced that it haspriced its public offering of 1,400,000 shares of common stock. Skystar...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148534&full=1<div id"releaseBody"><p>LAVAL, QUEBEC--(Marketwire - June 30, 2009) - Savaria Corporation ("Savaria" or the "Corporation") (TSX: <a href"http://www.marketwire.com/mw/stock.jsp?TickerTSX:SIS">SIS</a>), the second largest company in the accessibility industry in North America, today announced that it has commenced with the issuer bid for up to 4,000,000 common shares (14.8% of the issued and...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148535&full=1<div id"releaseBody"><p>PARSIPPANY, NJ--(Marketwire - June 30, 2009) - The Medicines Company (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerMDCO">MDCO</a>)announced today that in accordance with NASDAQ Marketplace Rule 5635, theCompany issued new inducement stock options to one new hire due toadditional hiring in connection with its global expansion.<p>The inducement...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148538&full=1<div id"releaseBody"><p>MONTREAL, QUEBEC--(Marketwire - June 30, 2009) - Ambrilia Biopharma Inc. (TSX: <a href"http://www.marketwire.com/mw/stock.jsp?TickerTSX:AMB">AMB</a>) announced today that it will hold its Annual and Special Meeting of Shareholders on Tuesday, August 4, 2009, at 10:30 am ET at Bourse de Montreal, La Tour de la Bourse, 800 Victoria Square, 4th Floor, Montreal, Quebec...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148582&full=1<div id"releaseBody"><p>BAGSVAERD, DENMARK--(Marketwire - July 01, 2009) - Status regarding Novo Nordisk's holdingof its own shares (30 June2009)<p><br>In continuation of the company's announcement dated 29 January 2009concerning a planned share repurchase programme, and pursuant toSection 204.25 of the New York Stock Exchange Listed Company Manual,this is to report that Novo...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148513&full=1STOCKHOLM, Sweden, July 1, 2009 (GLOBE NEWSWIRE) -- Diamyd Medical's President and CEO comments in the company's interim report today on several significant advances during the period, including the positive development of the company's Phase III program.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148540&full=1<p>WAYNE, Pa., July 1 /PRNewswire-FirstCall/ -- Encorium Group, Inc. , a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today provided an update to the expected timeframe surrounding its previously announced letter of intent...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148545&full=1SAN DIEGO--(BUSINESS WIRE)--Bio-Matrix Scientific Group Inc. (OTCBB:BMSN)(http://www.BMSN.us), a San Diego-based biotechnology research and development company specializing in cord blood and peripheral blood stem cells, today announced that it has been named Stock Pick by WallStreetCorner.com (http://www.wallstreetcorner.com/stockpick.html) for the second time since February of this year. WallStreetCorner...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148548&full=1(BUSINESS WIRE)--Pfizer: WHAT: An assistance program offered by Pfizer that can help unemployed Americans continue receiving their prescription medicines. The program is fully operational today, July 1.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148598&full=1(BUSINESS WIRE)--Biotechnology Industry Organization (BIO): WHAT: BIO President & CEO Jim Greenwood will moderate a panel discussion on eco-innovation during the National Academies symposium Opportunities and Challenges in the Emerging Field of Synthetic Biology. Experts in the field of synthetic biology will discuss possible applications of biotechnology to environmental cleanup and pollution reduction...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148544&full=1OAK BROOK, Ill.--(BUSINESS WIRE)--On July 1, 2009, Huhhot Xinheng Baide Biotechnology Co. Ltd., (Xinheng Baide), a 51%-owned subsidiary of Bio-Bridge Science, Inc., announced it had finished acquiring a raw bovine serum collection center in Beian City, Heilongjiang Province, China by purchasing serum production equipment at the facility. The purchase price is RMB 280,000 (approximately $41,176)...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148468&full=1OBERKOCHEN, Germany--(BUSINESS WIRE)--Today Carl Zeiss announces a series of launches covering a range of product and application innovations. The start of this series is marked by the next-generation analytical field emission scanning electron microscope the MERLIN. This instrument combines the up to now contradictory requirements of ultra-high resolution imaging and analytical capabilities. ...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148488&full=1NEW YORK--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of hosted clinical development solutions, today announced that Roche has selected Medidata Rave as its enterprise-wide electronic data capture (EDC) solution. Designed to more efficiently capture and manage data collection, Medidata Rave will enable global access of clinical trial data to all relevant Roche stakeholders...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148511&full=1LONDON--(BUSINESS WIRE)--Osmetech plc (LSE:OMH), a fast growing international molecular diagnostics company, is pleased to advise that Christopher Gleeson has been appointed non-executive Chairman, effective July 1, 2009. Jon Faiz Kayyem, the founder of Clinical Micro Sensors, and the inventor of the fundamental Osmetech eSensor technology, becomes Vice Chairman effective July 1, 2009.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148551&full=1Billerica, MA -- Tuesday, June 30, 2009 -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the launch of its new line of BD PureCoat cell culture surfaces designed to help life science researchers in the pharmaceutical and biotechnology industries, as well as the academic research community, improve cell performance and assay reproducibility.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148562&full=1Leiden, June 30th 2009 Today, ServiceXS announced that they have acquired the GeneTitanTM Instrument from Affymetrix which maximizes the productivity of their lab. The GeneTitanTM combines the hybridisation oven, fluidics processing and imaging device into one bench-top machine, automating the microarray experiments from array processing to data generation. With the newly acquired GeneTitanTM, ServiceXS...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148564&full=1Reno, Nevada (July 1, 2009) - Hamilton Robotics introduces MICROLAB NIMBUS NVS (NIMBUS Vacuum System), an integrated platform for automated vacuum-based separations. NIMBUS NVS integrates liquid handling workstation capabilities with a vacuum manifold, pump and collection device for solid-phase extraction (SPE) of analytes from complex biological mixtures in 96-well plate format. NIMBUS NVS is ideal...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148594&full=1CEO & Chairman Jim Walker of Octagon Research Solutions, Inc., a pioneer and leading provider of breakthrough software and services to the life sciences industry, today announced the release of the newest version of StartingPoint. StartingPoint is Octagon's global submission document authoring template suite which is designed to offer standardized templates and formatting functionality to those authoring...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148485&full=1DUBLIN, Ireland--(BUSINESS WIRE)--Amarin Corporation plc (NASDAQ: AMRN) today reported preliminary unaudited financial results for the six and twelve months ended December 31, 2008. For the six months ended December 31, 2008, Amarin reported a net loss of $13.3 million or $0.49 per share, compared with a net loss of $13.4 million or $1.29 per share, for the six months ended December 31, 2007. The results...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148515&full=1<p>NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) to discuss second quarter 2009 financial results.</p><p></p><p></p><p></p><p>Interested parties may access a live audio webcast of the conference call...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148537&full=1<div id"releaseBody"><p>SALT LAKE CITY, UT--(Marketwire - June 30, 2009) - Myriad Genetics, Inc. (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerMYGN">MYGN</a>)today announced that, based on preliminary estimates, it anticipatesreporting total molecular diagnostic revenue, which represents the bulk ofthe Company's revenue, of approximately $86 million for the fiscal ...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148541&full=1SPOKANE, Wash.--(BUSINESS WIRE)--Signature Genomic Laboratories has appointed two new laboratory directors, Drs. Marilyn Slovak, Ph.D., and J. Britt Ravnan, Ph.D. Signature, which performs diagnostic genetic testing of chromosome abnormalities in individuals with unexplained mental retardation and/or birth defects, anticipates the appointments will help the company manage its steadily increasing volume...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148519&full=1AUSTIN, Texas--(BUSINESS WIRE)--ResearchPoint, a leading global Contract Research Organization (CRO), announced that Becky Causey has joined the company as vice president of Clinical Operations. Causey, with over 18 years of clinical development experience in some of the worlds largest CROs, oversees ResearchPoints clinical operations, project management and monitoring groups. In her new role, she...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148539&full=1<p>FLAGSTAFF, Ariz., July 1 /PRNewswire/ -- SenesTech, Inc., a biotechnology corporation working on innovations for humane animal population management, announced the appointment of George M. Siegel as Vice President of Business Development.</p><p></p><p>Siegel has over 35 years of business development experience in executive management positions. He has served as Chairman of the Board of Directors...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148493&full=1MELBOURNE, Australia--(BUSINESS WIRE)--Avexa Limited (ASX:AVX) today announced the appointment of Lawrence Gozlan to its Board of Directors, replacing Dr John Sime who is retiring from the board. Dr Sime was appointed to the board as a non-executive director in June 2007, and Mr Gozlan will replace him in this capacity effective immediately.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148521&full=1SAN LEANDRO, Calif.--(BUSINESS WIRE)--Alpha Innotech Corp. (OTCBB:APNO), a leading provider of gel imaging systems for drug discovery and life science research, announced that Mssrs. Chris van Ingen and Dr. Shahram Hejazi were elected to its Board of Directors during the Companys most recent annual meeting.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148536&full=1<div id"releaseBody"><p>MISSISSAUGA, ON--(Marketwire - June 30, 2009) - <table class"releaseLink"><tr><td class"releaseLink"><b>Highlighted Links</b></td></tr><tr><td><p>&nbsp;</p><a href"http://www2.marketwire.com/mw/mmframe?prid515422&attachid1014490">MacReportMedia.com </a></td></tr><tr><td><p>&nbsp;</p><a href"http://www2.marketwire.com/mw/mmframe?prid515422&attachid1014489">HearAtLast...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148546&full=1PARIS--(BUSINESS WIRE)--At yesterday's Annual General Meeting, the members of France Biotech (the French association for life science entrepreneurs: www.france-biotech.org) voted to elect their governing bodies, in accordance with the organization's statutes. The newly elected Administrative Council then appointed Andr Choulika as Chairman. He succeeds the outgoing Chairman Philippe Pouletty MD, who...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148524&full=1SPOKANE, Wash.--(BUSINESS WIRE)--Signature Genomic Laboratories, which performs microarray-based diagnostic genetic testing of chromosome abnormalities in individuals with unexplained mental retardation and/or birth defects, today announced that President and CEO Dr. Lisa G. Shaffer, Ph.D. received the Ernst & Young Entrepreneur Of The Year 2009 Award in the Life Sciences category in the Pacific Northwest...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148543&full=1WEST PALM BEACH, Fla.--(BUSINESS WIRE)--BioFlorida, Floridas statewide association for the bioscience industry, announces a new awards ceremony at BioFloridas 12th Annual Conference taking place November 4 6, 2009 at the JW Marriott Orlando, Grande Lakes, Orlando, FL. The conference is the states largest gathering of life science professionals, and attendance is expected to reach more than 4...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148565&full=1Irvine, CA - June 2009 Quest International, Inc. announced it was once again the recipient of the biennially conferred, Siemens Healthcares Best Global Supplier of the Year Award. This is the second consecutive year the Irvine, California based company was presented with the award, receiving honors in 2006 as well.</p><p>Quest collected the prestigious award at the 2009 Siemens Annual Supplier...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148595&full=1London, 1 July, 2009 /PRNewswire/ Johnson & Johnson today announced that Axel Ullrich, Ph.D., director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, whose discoveries have led to novel cancer therapies including Herceptin (trastuzumab)*, is the winner of the 2009 Dr. Paul Janssen Award for Biomedical Research. An independent committee of world-renowned...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148542&full=1TRENTON, N.J. & MALVERN, Pa.--(BUSINESS WIRE)--BioNJ and Pennsylvania Bio announce that Biotech 2009: Imagine. Collaborate. Innovate (www.biotech2009.org) will be held on November 16-17, 2009 at a new location the Pennsylvania Convention Center in Philadelphia, Pennsylvania. Biotech 2009, the ninth annual joint symposium of the two state associations, is designed to advance the growth and development...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148547&full=1SAN DIEGO--(BUSINESS WIRE)--LifeVantage Corporation (OTCBB: LFVN), maker of Protandim, held its inaugural ribbon cutting event June 26 and June 27 in San Diego, California, at the Hilton San Diego Bayfront Hotel.Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148593&full=1BARCELONA, Spain, May 20, 2009 - Six months outcome of Sahajanand Medical Technologies Supralimus-Sirolimus Eluting stent with Bioabsorbable Polymer was presented at EuroPCR 2009. This analysis was performed as a part of the prospective of E-Series Multicenter Registry. The dataset demonstrates excellent results in high risk patients with complex coronary lesions, including high procedural success...Wed, 01 Jul 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148180&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148190&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=147972&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148234&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148169&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=147970&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148193&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148269&full=1CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ:POZN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric coated (EC) naproxen and immediate release esomeprazole. POZEN and AstraZeneca entered into a global co-development agreement for VIMOVO in August 2006. Pending...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148185&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148179&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148177&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148248&full=1<p>FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R) (armodafinil) Tablets [C-IV] for the indication of improved wakefulness in patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148181&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148240&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148175&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=147969&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148280&full=1CAMBRIDGE, Mass., June 29, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced top-line results from the EMINENCE (Evaluation of M118 in Percutaneous Coronary Intervention) phase 2 multicenter study of the intravenous formulation of M118. Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=147967&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148192&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148275&full=1<p>Heart Attack Patient Receives His Own Heart Stem Cells as Part of Medical Study to Determine Safety of New Technique to Repair Injured Heart Muscle </p><p></p><p>LOS ANGELES, June 30 /PRNewswire/ -- Doctors at the Cedars-Sinai Heart Institute announced today the completion of the first procedure in which a patient's own heart tissue was used to grow specialized heart stem cells that were then injected...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=147882&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148187&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=147947&full=1WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. today announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S. subsidiary, has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its new drug application (NDA) for alogliptin.</p><p>PPD is partnering with...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=147954&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148263&full=1CHARLOTTE, N.C., June 30, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has successfully reached its target enrollment of 82 patients for Study 302, the first of two pivotal Phase III clinical trials in Chelsea's registration program of Droxidopa for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148229&full=1LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, has filed a report with the U.S. Food and Drug Administrations (FDA) in response to the Agencys partial clinical hold on the Companys Phase 2b efficacy clinical trial with its molecular chaperone regulator drug candidate arimoclomol...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148238&full=1<p>SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa, including drug resistant isolates. Calixa is investigating CXA-...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148257&full=1SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil (AP), also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury (SCI). Doses of 20 and 30 mg of AP, given twice daily (BID), demonstrated statistically significant improvements compared to placebo for...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148251&full=1<p>Results Demonstrate Positive Proof of Mechanism</p><p></p><p>SAN DIEGO, June 30 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor.</p><p></p><p>The interim results demonstrate that a sustained pharmacodynamic (PD) effect can be achieved with a...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148255&full=1<p>- Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program -</p><p></p><p>- Inclusion of Patients with Diverse Advanced Cancers Along with Promising Interim Phase II Data Suggest Bavituximab Could Have Broad Anti-Cancer Utility -</p><p></p><p>TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. today announced that it has completed the planned patient...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148183&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148271&full=1SAN DIEGO, June 30, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. In addition, at least 75% of vaccinated animals achieved or exceeded the protection...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148203&full=1<p>Prospective Study Seeks to Assess RSV Burden in Outpatient Setting During First Year of Life; Reinforcing Commitment to Pediatric Research </p><p></p><p>GAITHERSBURG, Md., June 29 /PRNewswire/ -- MedImmune continues to advance its commitment to pediatric research with today's announcement of the first observational prospective study designed to assess the burden of respiratory syncytial virus ...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148204&full=1<p>febit Technology Enables the Conversion of New Sequence Data into Biochips for Gene Expression Profiling and Sequence Capture for Next-Generation Sequencing Within Days</p><p></p><p>LEXINGTON, Mass. and HEIDELBERG, Germany, June 29 /PRNewswire/ -- febit holding gmbh announced today the launch of the first biochip on the market covering the newly published whole mouse genome. The biochip from febit...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148346&full=1<p>SAN DIEGO, June 30 /PRNewswire/ -- Accumetrics, Inc. announces that it has reached the halfway mark (1,600 patients) in the enrollment of its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148348&full=1<p> AMSTERDAM, The Netherlands, June 30 /PRNewswire/ --</p><p> - "Study Could Have Major Impact on the Decision-Making Process With Respect to Infertility Treatment"</p><p> New data from an economic analysis presented today at this year's European Society of Human Reproduction and Embryology (ESHRE) congress showed that, within the parameters of the simulation model used, the in vitro fertilisation...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148349&full=1<p>Data shows a very high percentage of women responded favorably to a bioidentical and FDA approved hormone therapy for hot flashes</p><p></p><p>MAPLE GROVE, Minn., June 30 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. presented the results of a secondary analysis to determine the response rates to three doses of transdermal Divigel(R) (estradiol gel) 0.1 percent at the recent 57th Annual Clinical...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148237&full=1CARLSBAD, Calif.--(BUSINESS WIRE)--Life Technologies Corporation (NASDAQ: LIFE), a provider of innovative life science solutions, today announced that it has signed a definitive agreement to sell its SQL*LIMS business to LabVantage Solutions, Inc. for an undisclosed amount.Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148313&full=1SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced today the acquisition of an extensive collection of issued and pending patents from Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq:PGLA), a globally focused biotechnology company. The patents claim compositions and methods related to transporter molecules that...Tue, 30 Jun 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=148199&full=1<p>MONHEIM, Germany and ST. LOUIS, June 29 /PRNewswire/ -- Bayer CropScience AG and Monsanto Company have agreed to cross license their respective herbicide tolerance traits in rapeseed/canola on a non-exclusive basis for commercialization within their respective branded canola seed businesses. Canola is a form of rapeseed primarily grown in North America and Australia. </p><p></p><p>Under the terms...Tue, 30 Jun 2009 12:00:00 AM GMT